Editors

About the Editor

Series Editors

Prof. Michael J. Parnham, PhD, C.Biol.FRSB, FBPhS studied Pharmacology at Chelsea (now King's) College London, including a year in the Pharmacology Department of subsequent Nobel Prize winner, John R. Vane, at the Royal College of Surgeons. He received his PhD from Bristol University in 1976 and carried out postdoctoral research on prostaglandins and chronic inflammation with Ivan Bonta at Erasmus University Rotterdam, The Netherlands for which he was awarded the Goslings Prize of the Netherlands Society for Antirheumatic Therapy. From 1980, he spent a decade in anti-inflammatory drug research with A. Nattermann and subsequently, Rhȏne-Poulenc in Cologne, Germany. He and his colleagues received in 1990 the Prix Galien Germany for development of a novel organoselenium approach to anti-inflammatory therapy. In the same year, Dr. Parnham established a consultancy in Bonn and gained his Habilitation at Goethe University Frankfurt where he taught immunopharmacology to pharmacists. Appointed Professor in Frankfurt in 1998, Dr. Parnham established laboratories in pharmacology and toxicology at PLIVA Pharmaceuticals, developing biosimilar agents and working on novel anti-inflammatory macrolides. Following acquisition by GSK in 2006, he was Director of Preclinical Discovery. From 2012 to 2019, Prof. Parnham built up preclinical research in the Fraunhofer Institute of Molecular Biology & Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP, in Frankfurt am Main. On retiring from IME-TMP, he co-founded in Germany/Switzerland the spin-off Phialogics, developing novel biologics for autoimmune diseases, and is Chairman of the Scientific Advisory Board. Following a period as Chief Scientific Officer, he is currently Senior Advisor at EpiEndo Pharmaceuticals, Rejkjavik, continuing to work on macrolides and respiratory inflammation.

Prof. Parnham was co-founder in 1983 of the European Workshop on Inflammation, and its secretary until 1999. During this time he was Co-Editor of the peer-reviewed journal Agents and Actions, presiding as Managing Editor (1992-2013) over its transformation to Inflammation Research. He is co-editor of the monograph series Progress in Inflammation Research (PIR) and of Milestones in Drug Therapy (MDT) as well as of the textbook, Principles of Immunopharmacology, now in its 4th edition. He is also Editor-in-Chief of the Springer Reference Compendium of Inflammatory Diseases and of the three-volume monograph Discoveries in Pharmacology. Prof. Parnham has lectured extensively and organised symposia on various aspects of immunopharmacology and anti-inflammatory therapy and has published more than 200 peer-reviewed articles. In 2015, he received a Lifetime Achievement Award from the International Association of Inflammatory Societies (IAIS).

Dr. Francis Man, MSc, PharmD, PhD studied Pharmacy and Chemical Biology at the University of Strasbourg, France. After working at the European Pharmacopoeia (EDQM), he obtained his PhD in Chemical Biology from King’s College London in 2016, conducting research into the anti-inflammatory mechanisms of mycobacteria-derived peptides. He then joined the Department of Imaging Chemistry and Biology at King’s College London as a postdoctoral researcher, where he developed novel PET radiotracers to image cell therapies and nanomedicine delivery. His research has also focused on developing novel imaging methods for non-invasive evaluation of platelet and epithelial dysfunction in lung inflammation. Currently, he is a Senior Scientist at GE HealthCare, where he is responsible for the preclinical development of novel radiotracers and MRI contrast agents. He recently co-edited “Imaging Inflammation” in the Progress in Inflammation Research (PIR) book series.

This series in indexed in Scopus.